课题基金 / 基金详情

Tissue specific role of IFNalpha/beta and IFNgamma in innate immuniy to prio path

Tissue specific role of IFNalpha/beta and IFNgamma in innate immuniy to prio path
IFNα/β 和 IFNγ 在先天免疫中的组织特异性作用
批准号:
7672130
负责人:
ROBERT DAVID SCHREIBER
金额:
$35.94万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-04-09 至 2014-02-28

项目摘要

项目成果

ROBERT DAVID SCHREIBER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Type I Interferons (the family of IFNa proteins and IFNp) and Type II IFN (IFNy) play central and essential roles in promoting innate immunity against a wide variety of viruses, bacteria and parasites. The IFNs induce not only cell-intrinsic mechanisms that protect host cells against pathogen infection but also activate a variety of cell-extrinsic mechanisms leading to activation of NK cells, macrophages, polymorphonuclear leukocytes and T cells that destroy infected cells. Our knowledge of IFN biology has stemmed largely from in vitro experiments performed on IFN-responsive versus unresponsive cells and in vivo approaches in which IFN responsiveness is globally ablated in mice through use of neutralizing or blocking monoclonal antibodies or through disruption of genes encoding either the IFN species themselves or their respective receptors. The physiologic relevance of these studies have been validated by the discovery of humans who have distinct defects in either producing or responding to the various forms of IFN. However, since the receptors for IFNa/p or IFNy are expressed on nearly all cells, we still know very little about the cell-specific functions of these cytokines in vivo. Since the IFNs play such a key role in innate immunity, obtaining a more detailed understanding of their common and unique effects on different cell populations is not only needed but essential if we wish to intentionally stimulate innate immunity, either prophylactically or therapeutically, to protect us against naturally-occurring (e.g. pandemic viral infections) or intentionally-produced (e.g., bioterrorism) infections. Armed with (1) an extensive understanding of IFN biology that the Schreiber lab has gained from molecular and genetic experiments conducted over the last 28 years (2) a comprehensive knowledge that exists within the Unanue laboratory about the immunobiology of Listeria monocytogenes infection, and (3) the particularly broad and deep understanding of virology that the other members of this MRCE program bring to this application, we propose to produce and study mice on a stabilized C57BL/6 genetic background that lack responsiveness to IFNa/p or IFNy in specific cell types to define the tissue specific actions of the IFNs to infection with priority pathogens.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
DEVELOPMENT OF GENOMICS BASED PERSONALIZED CANCER IMMUNOTHERAPY
  • 批准号:
    8887618
  • 项目类别:
  • 资助金额:
    $46.91万
  • 财政年份:
    2015
  • 负责人:
    ROBERT DAVID SCHREIBER
  • 依托单位:
DEVELOPMENT OF GENOMICS BASED PERSONALIZED CANCER IMMUNOTHERAPY
  • 批准号:
    9031745
  • 项目类别:
  • 资助金额:
    $44.9万
  • 财政年份:
    2015
  • 负责人:
    ROBERT DAVID SCHREIBER
  • 依托单位:
Genetics Core
  • 批准号:
    8379365
  • 项目类别:
  • 资助金额:
    $23.36万
  • 财政年份:
    2012
  • 负责人:
    ROBERT DAVID SCHREIBER
  • 依托单位:
Tissue specific role of IFNalpha/beta and IFNgamma in innate immuniy to prio path
  • 批准号:
    8234935
  • 项目类别:
  • 资助金额:
    $36.23万
  • 财政年份:
    2011
  • 负责人:
    ROBERT DAVID SCHREIBER
  • 依托单位:
海外基金